Loading…
Accretion Nutraveda (BSE 544694)₹329.00+5.79%Pharmaceuticals
Accretion Nutraveda is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 47.2 against a peer median of 22.1, and ROCE of 27.8% against a peer median of 12.1%, and latest-quarter sales growth of 80.4% against a peer median of 18.7%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ambalal Sarabhai Enterprises | 276 | 20.6 | 12.1 | 12.3 | 0.36 | 0.0 | 202 | 18 | 7.9 | −51.5 | vs BSE 544694 |
| Astal Laboratories | 263 | 17.3 | 9.0 | 8.0 | 0.15 | 0.0 | 249 | 15 | — | — | vs BSE 544694 |
| Everest Organics | 255 | 44.6 | 12.0 | 7.6 | 0.66 | 0.0 | 196 | 6 | 19.2 | −9.7 | vs BSE 544694 |
| Sat Kartar Life | 245 | 14.2 | 36.0 | 26.5 | 0.04 | 0.5 | 201 | 17 | 26.7 | 28.4 | vs BSE 544694 |
| BDH Industries | 240 | 22.1 | 19.9 | 14.8 | 0.03 | 1.2 | 96 | 11 | 62.8 | 15.6 | vs BSE 544694 |
| Zenotech Laboratories | 238 | — | 4.6 | −1.2 | 0.00 | 0.0 | 44 | −1 | 10.2 | −145.0 | vs BSE 544694 |
| Accretion Nutraveda | 237 | 47.2 | 27.8 | 25.1 | 0.12 | 0.0 | 34 | 5 | 80.4 | 56.1 | — |
| Accretion Pharmaceuticals | 225 | 23.3 | 28.9 | 27.6 | 0.23 | 0.0 | 89 | 10 | 18.2 | 13.9 | vs BSE 544694 |
| Gennex Laboratories | 218 | 11.2 | 11.0 | 9.2 | 0.36 | 0.0 | 173 | 21 | 16.5 | −6.8 | vs BSE 544694 |
| Sanjivani Paranteral | 214 | 28.8 | 18.0 | 15.6 | 0.30 | 0.3 | 69 | 7 | 33.3 | 44.2 | vs BSE 544694 |
| Kerala Ayurveda | 212 | — | −10.0 | −161.1 | 7.83 | 0.0 | 131 | −16 | 15.9 | −500.5 | vs BSE 544694 |
| Peer median | 238 | 22.1 | 12.1 | 12.3 | 0.23 | 0.0 | 131 | 10 | 18.7 | 3.6 |
Listed companies closest to Accretion Nutraveda in Pharmaceuticals include Ambalal Sarabhai Enterprises, Astal Laboratories, Everest Organics, Sat Kartar Life, BDH Industries, Zenotech Laboratories, Accretion Pharmaceuticals, Gennex Laboratories.
Ambalal Sarabhai Enterprises, with a market cap of ₹276 Cr.
Accretion Nutraveda trades at a P/E of 47.2; the median of its peer set is 22.1. A P/E above or below the median is a description, not a judgement on value.
Accretion Nutraveda's return on capital employed is 27.8%, above the peer median of 12.1%.